Unresectable Leiomyosarcoma
Drug | Drug Name | Drug Description |
---|---|---|
DB05109 | Trabectedin | An alkylating agent approved for the treatment of unresectable or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB05109 | Trabectedin | Cytochrome P450 3A4 | enzyme |
DB05109 | Trabectedin | Cytochrome P450 2C9 | enzyme |
DB05109 | Trabectedin | Cytochrome P450 2D6 | enzyme |
DB05109 | Trabectedin | Cytochrome P450 2E1 | enzyme |
DB05109 | Trabectedin | Cytochrome P450 2C19 | enzyme |
DB05109 | Trabectedin | DNA | target |
DB05109 | Trabectedin | Prostaglandin G/H synthase 1 | enzyme |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB11105 | Benzalkonium | 1 | Suspended | 1 |
DB00997 | Doxorubicin | 1 | Completed | 1 |
DB00997 | Doxorubicin | 1 | Suspended | 1 |
DB16252 | Nedisertib | 1 | Suspended | 1 |
DB11730 | Ribociclib | 1 | Completed | 1 |
DB00759 | Tetracycline | 1 | Suspended | 1 |
DB11945 | Avelumab | 1 / 2 | Terminated | 1 |
DB06589 | Pazopanib | 1 / 2 | Terminated | 1 |
DB11836 | Sapanisertib | 1 / 2 | Terminated | 1 |
DB05109 | Trabectedin | 1 / 2 | Terminated | 1 |
DB08875 | Cabozantinib | 2 | Active Not Recruiting | 1 |
DB06186 | Ipilimumab | 2 | Active Not Recruiting | 1 |
DB11793 | Niraparib | 2 | Withdrawn | 1 |
DB09035 | Nivolumab | 2 | Active Not Recruiting | 1 |
DB00853 | Temozolomide | 2 | Active Not Recruiting | 1 |
DB09074 | Olaparib | 2 / 3 | Not Yet Recruiting | 1 |
DB09074 | Olaparib | 2 / 3 | Recruiting | 1 |
DB06589 | Pazopanib | 2 / 3 | Not Yet Recruiting | 1 |
DB06589 | Pazopanib | 2 / 3 | Recruiting | 1 |
DB00853 | Temozolomide | 2 / 3 | Not Yet Recruiting | 1 |
DB00853 | Temozolomide | 2 / 3 | Recruiting | 1 |
DB05109 | Trabectedin | 2 / 3 | Not Yet Recruiting | 1 |
DB05109 | Trabectedin | 2 / 3 | Recruiting | 1 |